载脂蛋白E基因多态性与阿托伐他汀调脂疗效的相关性Correlation between polymorphisms of ApoE gene and the lipid regulatory effect of atorvastatin
孙丹,孙玉坤,惠福海,史国兵,赵庆春
SUN Dan1,2,SUN Yu-kun3,HUI Fu-hai3,SHI Guo-bing1
摘要(Abstract)：
目的研究载脂蛋白E基因多态性与阿托伐他汀调脂疗效及肝功影响的相关性。方法采用多聚酶链式反应-限制性内切酶片段长度多态性方法(PCR-RFLP)测定49例血脂异常患者ApoE基因型,测定服用阿托伐他汀治疗前及治疗4周后的血脂及肝功水平,分析基因型与调脂疗效的关系。结果 E3等位基因组服用阿托伐他汀4周后,总胆固醇(TC)降低有统计学意义(P<0.05),而E2、E4等位基因组对血脂水平的降低不明显;各等位基因组间的指标变化程度经过统计分析发现差异无统计学意义。服用阿托伐他汀后E3等位基因的STB与ALT改变较大,但各等位基因组间的肝功指标变化程度差异无统计学意义。结论载脂蛋白E基因多态性对阿托伐他汀调脂疗效差异无统计学意义,对肝功损害无显著影响。
Objective To study the relationship between apolipoprotein-E(ApoE) restricted fragment length polymorphism and the therapeutic effect of atorvastatin. Methods ApoE genotypes of 49 subjects were tested by means of polymerase chain reaction and restricted fragment length polymorphism.The levels of lipid profile in different genotype patients before and after atorvastatin therapy were compared.Then the association of them with SPSS software was analyzed. Results After 4 weeks,the group carrying the E3 allele had more responsive than E2 and E4 allele in total cholesterol(TC)(P>0.05).But the ApoE locus did not account for any significant fraction of the variability in response.At the same time,STB and ALT changed worse in the group carrying E3 allele,but on significant between all groups. Conclusions ApoE genetic polymorphism may have no significant effect on atorvastatin treatment and adverse reactions of hepatic function.
关键词(KeyWords)：
载脂蛋白E;他汀类;基因多态性;血脂;肝功
apolipoprotein E;statins;gene polymorphism;lipid;hepatic function
基金项目(Foundation):
作者(Author):
孙丹,孙玉坤,惠福海,史国兵,赵庆春
SUN Dan1,2,SUN Yu-kun3,HUI Fu-hai3,SHI Guo-bing1
DOI: 10.14066/j.cnki.cn21-1349/r.2011.02.008
参考文献(References)：
- [1]LAROSA J C.Statins and risk of coronary heart disease[J].Am Med Association,2000,283:2935-2936.
- [2]LEE E,RYAN S,BIRMINGHAM B,et al.Rosuvastatinpharmacokinetics and pharmacogenetics in white and A-sian subjects residing in the same environment[J].ClinPharmacol Ther,2005,78:330-341.
- [3]PERSIDIS A.Pharmacogenonics and diagnostics[J].Nat Biotechnol,1998,16:791-792.
- [4]PEDRO-BOTET J,SCHAEFER E J,BAKKER-ARKE-NA R G,et a1.Apolipoprotein E genotype affects plasmalipid response to atorvastatin in a gender specific manner[J].Atherosclerosis,2001,158(1):183-193.
- [5]BALLANTYNE C M.Current and future aims of lipid-lowering therapy:changing paradigms and lessons fromthe heart protection study on standards of efficacy andsafety[J].Am Cardiol,2003,92:3-9.
- [6]PENA R,LAHOZ C,MOSTAZA J M,et al.Effect ofApoE genotype on the hypolipidaemic response topravastatin in an outpatient setting[J].Intern Med,2002,251:518-525.
- [7]邹琛.他汀的药物基因组学研究进展[J].中国药理学通报,2006,22(2):133-136.